Ose Immuno: share price falls, broker lowers target
The analyst reports that on Friday after trading, OSE Immuno announced that it had regained the rights to OSE-127 after Servier decided not to pursue development of this asset following the failure of Phase IIa in Sjögren's syndrome.
' As a reminder, in 2016, the two groups had entered into a collaboration to address autoimmune diseases with OSE-127 as part of 2 clinical trials conducted in parallel. Servier had placed a license option on OSE-127, which it therefore decided not to exercise, thereby cancelling out the potential for an associated milestone of 15mE ', the analyst points out.
Invest Securities has thus adjusted its model by withdrawing the Sjögren's syndrome program line, but remains positive in view of the potential represented by OSE's entire pipeline.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction